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Several studies have shown that intensive treatment with statins is more 
effective than moderate therapy reducing the incidence of cardiovascular events after an 
Acute Coronary Syndrome (ACS). However, the processes involved in this clinical 
benefit are not entirely clarified yet. In order to elucidate the potential effects of 
intensive statin treatment, immunodepleted plasma samples from ACS patients were 
analyzed by 2-DE and 2D-DIGE. Twenty-five patients with ACS were randomized, the 
fourth day after admission, to receive atorvastatin 80 mg/dL (ATV) or standard therapy 
for two months, when plasma samples were collected and immunodepleted. These two 
groups were compared with healthy subjects, matched for age and sex. Changes in 
expression levels of 17 protein spots were revealed by 2-DE, but only one spot was 
affected by both treatments. ATV normalized 9 spots with respect to standard therapy 
and expression levels of other 7 spots were modified only by ATV. 2D-DIGE analysis 
showed altered expression levels in 33 protein spots, and both treatments affected15 of 
them. 14 different spots were normalized by ATV, but this treatment also modified 
expression levels of 4 different spots. The identified proteins were involved in several 
physiological processes that may be related to the benefits of high-dose statin therapy. 
This study might improve our understanding of the molecular mechanisms involved in 
the clinical advantage of this intensive treatment. 
